ADVERTISEMENT
Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding
Park City, Utah – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for patients with Peripheral Artery Disease (PAD), Critical Limb Ischemia (CLI), Coronary Artery Disease (CAD), and End Stage Renal Disease (ESRD), has successfully completed its Series B funding round. This milestone supports Transit Scientific’s mission to advance patient care through medical device innovation.
This Series B funding highlights the escalating demand for revolutionary vessel prep technologies and underpins ongoing pipeline product development at Transit Scientific. The company’s existing portfolio comprises 36 FDA-cleared devices, including the XO Score 6Fr Angioplasty Sheath Platform, 2Fr XO Cross 14 Microcaths, 2.6Fr XO Cross 18 Microcaths, and 3.8Fr XO Cross 35 Support Catheters, as well as the recently cleared XO Score 3.8Fr and 2.2Fr Low-Profile Angioplasty Sheath Platforms.
The persistent demand for innovative and transformative vessel preparation technologies remains evident due to increasing procedural complexity, unmet needs, and advancement of disease states in PAD, CLI, and CAD. Current treatment options for advanced arterial and venous diseases encompass scoring and cutting angioplasty devices, angioplasty constraining structures, high-pressure PTA (Percutaneous Transluminal Angioplasty), and occasionally, atherectomy. Scoring and cutting angioplasty devices are engineered for precise force application in challenging lesions to dilate and prepare vessels for further intervention. In contrast, angioplasty constraining devices are designed to facilitate controlled dilatation and balloon rewrap, and to minimize “dog-boning” during balloon angioplasty procedures. Both technologies equip physicians with additional tools to improve patient outcomes while minimizing complications.
“Our focus remains on delivering devices that improve patient outcomes and advance the practice of interventional, cardiac, and vascular medicine” said Greg Method, President & CEO of Transit Scientific. “This funding will enable us to continue working closely with clinicians to develop unique solutions that meet their patients’ evolving needs.”
Transit Scientific extends gratitude to its investors and partners for their continued support. The company is excited to enter the next phase of growth, where it will continue to make strides in enhancing medical device technology and, ultimately, patient care.
Transit Scientific is a privately held company dedicated to designing, developing, and commercializing medical devices. Their portfolio includes FDA-cleared XO Score® and XO Cross® platforms, as well as the XO Cath Interventional Oncology and XO CS Constrain for peripheral and coronary procedures currently in development, supported by over 20 issued and pending U.S. and global patents.
For more information, visit www.xoscore.com
Find More:
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
